CCL5 and Alzheimer disease: On the contrary, CCL5 levels in D3 lysates were increased in the BBB models with PBMCs from control patients (a 37.34-fold increase), from mild AD patients (a 36.07-fold increase) and from moderate AD patients (by 18.75-fold increase) versus D3 lysates in BBB model without PBMCs (Table 2).